Objective: Our aim was to analyze the effectiveness of safinamide on pain in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in Parkinson´s disease patients) study .
Background: Some studies observed a benefit of Parkinson´s disease patients after treatment with safinamide in some non-motor symptoms such as pain, mood, sleep or cognition.
Method: SAFINONMOTOR is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V1) to the end of the observational period (6 months) (V4) in the Non-Motor Symptoms Scale total score. In this analysis, a secondary objective of the study, the score in the KPPS (King´s PD Pain Scale) at V1 and V4 were compared. Wilconxon´s rank sum test was performed for testing the changes from V1 to V4.
Results: 50 patients were included between May/2019 and February/2020 (age 68.5 ± 9.12 years; 58% women; 6.4 ± 5.1 years from diagnosis). At 6 months, 44 patients completed the follow-up (88%). The KPPS total score was reduced by 43.6% (from 40.04 ± 36.18 in V1 to 22.60 ± 21.42 in V4; p<0.0001). By domains, improvement was observed in musculoskeletal pain (-35.9%; p=0.009), fluctuation-related pain (-51.7%; p=0.020), nocturnal pain (-46.1%; p=0.001), discoloration/edema/swelling (-50.4%; p=0.009) and radicular pain (-40.1%; p=0.048). A moderate correlation between the change in quality of life (PDQ-39SI [39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index] from V1 to V4) and pain (KPPS from V1 to V4) was observed (r=0.326; p=0.038). A total of 21 adverse events in 11 patients (22%) were reported, 5 of which were severe (not related to safinamide).
Conclusion: Safinamide is well tolerated and improves pain in PD patients at 6 months. Well-designed studies are necessary to analyze in detail the possible beneficial effect of safinamide on pain in PD patients.
References: 1. Santos García D, Labandeira Guerra C, Yáñez Baña R, et al. Safinamide Improves Non-Motor Symptoms Burden in Parkinson´s Disease: An Open-label Prospective Study. Brain Sciences 2021 (in press).
To cite this abstract in AMA style:R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García. Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study. [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/safinamide-improves-pain-in-parkinsons-disease-results-from-the-safinonmotor-study/. Accessed November 29, 2023.
« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/safinamide-improves-pain-in-parkinsons-disease-results-from-the-safinonmotor-study/